With extended applications, Tapestri Designer, the only AI-powered cloud-based tool for single-cell panel designs, will improve drug development and CRISPR quality control studies South San Francisco, CALIF...
Gene editing
FDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with Intellia Therapeutics
CAMBRIDGE, Mass., March 31, 2020 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in...
